SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer (SUGAR)
Sponsor: Bayer
Listed as NCT05826509, this PHASE2 trial focuses on Prostate Cancer and remains ongoing. Sponsored by Bayer, it has been updated 18 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
18 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Oct 2025 — Dec 2025 [monthly]
Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE2
▶ Show 13 earlier versions
-
Apr 2025 — Aug 2025 [monthly]
Recruiting PHASE2
-
Oct 2024 — Apr 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Oct 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Institut Claudius Regaud
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Bordeaux, France , Créteil, France , Grenoble, France , Lille, France , Lyon, France , Marseille, France , Paris, France , Pierre-Bénite, France , Quint-Fonsegrives, France and 4 more locations